Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Ovarian Neoplasms 6Carcinoma, Ovarian Epithelial 4Sarcoma, Synovial 2Sarcoma, Endometrial Stromal 2Neurofibrosarcoma 2Malignant mesenchymal tumor 2Liposarcoma 2Leiomyosarcoma 2Hemangiosarcoma 2Fallopian Tube Neoplasms 2Uterine Neoplasms 1Thymoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma, Ewing 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Rhabdomyosarcoma, Embryonal 1Rhabdomyosarcoma 1Recurrent Uterine Sarcoma 1Recurrence 1Primary Myelofibrosis 1Pleural Neoplasms 1Osteosarcoma 1Neoplasms 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Mastocytosis 1Leukemia, Mast-Cell 1

Interventions

temsirolimus 1Sorafenib 1Sirolimus 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recurrent Uterine Sarcoma × Imatinib Mesylate × Gynecologic × Clear all
NCT00075400 2019-07-24

Imatinib Mesylate in Treating Patients With Recurrent or Persistent Uterine Cancer

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 11 charts
GynecologicSarcoma

Recurrent Uterine Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡